Christopher Yea Kal Vista Pharmaceuticals, Inc. (KALV) insider trading activity

Christopher Yea is CHIEF DEVELOPMENT OFFICER of KalVista Pharmaceuticals, Inc.. Currently has a direct ownership of 223,508 shares of KALV, which is worth approximately $2.98 Million. The most recent transaction as insider was on Nov 24, 2025, when has been sold 4,331 shares (Common Stock) at a price of $13.45 per share, resulting in proceeds of $58,251. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 224K

69.26% 3M change

145.23% 12M change

Total Value Held $2.98 Million

Christopher Yea Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 24 2025	SELL Open market or private sale	$58,251 $13.45 p/Share	4,331 Reduced 1.9%	223,508 Common Stock
Nov 22 2025	BUY Exercise of conversion of derivative security	-	3,125 Added 1.35%	227,839 Common Stock
Nov 21 2025	BUY Exercise of conversion of derivative security	-	3,750 Added 1.64%	224,714 Common Stock
Nov 20 2025	BUY Exercise of conversion of derivative security	-	87,390 Added 28.34%	220,964 Common Stock
Nov 18 2025	SELL Open market or private sale	$38,849 $14.48 p/Share	2,683 Reduced 1.97%	133,574 Common Stock
Nov 17 2025	BUY Exercise of conversion of derivative security	-	4,205 Added 2.99%	136,257 Common Stock
Aug 25 2025	SELL Open market or private sale	$26,222 $13.42 p/Share	1,954 Reduced 1.46%	132,052 Common Stock

Aug 22 2025	SELL Open market or private sale	$31,225 $13.22 p/Share	2,362 Reduced 1.77%	130,881 Common Stock
Aug 22 2025	BUY Exercise of conversion of derivative security	-	3,125 Added 2.28%	134,006 Common Stock
Aug 21 2025	BUY Exercise of conversion of derivative security	-	3,750 Added 2.74%	133,243 Common Stock
Aug 18 2025	SELL Open market or private sale	$34,940 $13.19 p/Share	2,649 Reduced 2.0%	129,493 Common Stock
Aug 17 2025	BUY Exercise of conversion of derivative security	-	4,203 Added 3.08%	132,142 Common Stock
Jul 09 2025	SELL Open market or private sale	$474,622 $15.69 p/Share	30,250 Reduced 19.12%	127,939 Common Stock
Jul 08 2025	BUY Grant, award, or other acquisition	-	60,000 Added 27.5%	158,189 Common Stock
May 23 2025	SELL Open market or private sale	$21,783 $11.31 p/Share	1,926 Reduced 1.92%	98,189 Common Stock
May 22 2025	SELL Open market or private sale	$27,525 $11.88 p/Share	2,317 Reduced 2.33%	96,990 Common Stock
May 22 2025	BUY Exercise of conversion of derivative security	-	3,125 Added 3.03%	100,115 Common Stock
May 21 2025	BUY Exercise of conversion of derivative security	-	3,750 Added 3.64%	99,307 Common Stock
May 19 2025	SELL Open market or private sale	$30,784 $11.84 p/Share	2,600 Reduced 2.65%	95,557 Common Stock
May 17 2025	BUY Exercise of conversion of derivative security	-	4,205 Added 4.11%	98,157 Common Stock
Feb 24 2025	SELL Open market or private sale	$19,218 $10.02 p/Share	1,918 Reduced 2.0%	93,952 Common Stock
Feb 22 2025	BUY Exercise of conversion of derivative security	-	3,125 Added 3.16%	95,870 Common Stock
Feb 18 2025	SELL Open market or private sale	$25,541 $9.82 p/Share	2,601 Reduced 2.73%	92,745 Common Stock
Feb 17 2025	BUY Exercise of conversion of derivative security	-	4,204 Added 4.22%	95,346 Common Stock
Nov 26 2024	SELL Open market or private sale	$19,374 $9.87 p/Share	1,963 Reduced 2.11%	91,142 Common Stock

Christopher Yea

CHIEF DEVELOPMENT OFFICER

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALV shares.

Notify only if

Value

Insider Trading

Get notified when an Kal Vista Pharmaceuticals, Inc. insider buys or sells KALV shares.

Notify only if

Operation

Value

Type

News

Receive news related to KalVista Pharmaceuticals, Inc.

Track Activities on KALV

Account